Definitive Contract HHSN261201500074C

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Icagen, Inc. for a Small Business Innovation Research (SBIR) Phase I project titled "SYSTEMIC TARGETED RADIONUCLIDE THERAPY FOR CANCER TREATMENT". The period of performance is from September 22, 2015 to June 21, 2016, with an ultimate completion date of September 30, 2016. This contract was not set aside for a specific business size or type. The goal of this SBIR...

<p>This is a $298,934 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Houston Pharmaceutical Inc., a small business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to develop a Targeted Radionuclide Therapy for Pancreatic Cancer. The contract has a period of performance through December 31, 2017. This award represents a set-aside for small businesses.</p>

<p>This is a $1,903,095.00 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Shuttle Pharmaceuticals, Inc. on September 9, 2019. The contract is for TOPIC 345: PREDICTIVE BIOMARKERS OF PROSTATE CANCER PATIENT SENSITIVITY FOR RADIATION LATE EFFECTS, with a period of performance through March 15, 2022. The contract does not have a set-aside designation.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute, part of the National Institutes of Health at the Department of Health and Human Services. The $399,989 Firm Fixed Price contract was awarded to Molecular Targeting Technologies, Inc. (MTTI) on September 18, 2017 to develop a cancer-selective, phosphatidylserine (PS)-targeted radiolabeled nanovesicle system for targeted radionuclide therapy of brain tumors. The contract has a...

This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Radiopharmaceutical Imaging and Dosimetry, LLC, doing business as Radiopharmaceutical Imaging &amp; Dosimetry LLC, a small business. The contract, valued at $299,275, is for a Small Business Innovation Research (SBIR) Phase I project to optimize targeted radionuclide therapy for metastatic liver cancer patients. This contract supports the NCI's broader...

<p>This is a $199,386 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Sensopath Technologies, Inc., a woman-owned small business. The contract is for &quot;TAS::75 0849::TAS TARGETED TWO-PHOTON PHOTODYNAMIC THERAPY TRIADS&quot; and has a period of performance through July 8, 2011. The contract was set aside for small businesses.</p>

The National Cancer Institute (NCI) awarded a $1,964,216.00 Firm Fixed Price contract to Pact &amp; Health LLC, a small business, for the development of an &quot;I-PARTS Integrated Platform for Anti-Cancer Radiation Therapeutics Screening&quot; under TOPIC 366. The contract has a period of performance through June 15, 2022. This contract is a definitive contract and was set aside for small businesses. The I-PARTS platform aims to support the NCI's research efforts in developing new...

This contract was awarded by the National Cancer Institute, a civilian agency, to Radiomedix, Inc., a small disadvantaged business, for the Targeted Radionuclide Therapy of Neuroendocrine Tumors Using Pb212-Octreotate Analogs project. The contract has a ceiling value of $298,132.00 and was awarded under the Small Business Innovation Research (SBIR) Program Phase I. The contract is a Definitive Contract with a Firm Fixed Price pricing type and has an ultimate completion date of August 18, 2017.

<p>This is a $299,813 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Hylapharm LLC, a self-certified small disadvantaged business, under the SBIR Program Phase I. The contract is for the development of &quot;Targeted Nanoparticle Treatment for Breast Cancer Stem Cells.&quot; This contract has a Total Small Business set-aside designation. The contract has an ultimate completion date of September 17, 2016.</p>